Dr. Hawk is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
210 E Welsh Pool Road
Exton, PA 19341Phone+1 551-284-9754- Is this information wrong?
Summary
- Dr. Natalyn Hawk is a hematologist-oncologist and director of clinical research in early drug development in Exton, PA. She received her medical degree from The Warren Alpert Medical School of Brown University and has been in practice 19 years. She is experienced in hepatocellular carcinoma, esophageal cancer, gastric cancer, renal cell carcinoma, and endometrial carcinoma. She has more than 10 publications and over 400 citings.
Education & Training
- Emory University School of MedicineFellowship, Hematology and Medical Oncology, 2007 - 2010
- Johns Hopkins University/Bayview Medical CenterResidency, Internal Medicine, 2003 - 2006
- The Warren Alpert Medical School of Brown UniversityClass of 2003
Certifications & Licensure
- GA State Medical License 2010 - 2025
- TN State Medical License 2021 - 2024
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 26 citationsPhase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhi...Ana Arance, Luis de la Cruz-Merino, Teresa M Petrella, Rahima Jamal, Lars Ny, Ana Carneiro, Alfonso Berrocal, Ivan Márquez-Rodas, Anna Spreafico, Victoria Atkinson, Fe...> ;Journal of Clinical Oncology. 2023 Jan 1
- 152 citationsModified FOLFIRINOX regimen with improved safety and maintained efficacy in pancreatic adenocarcinoma.Hemchandra Mahaseth, Edith Brutcher, John S. Kauh, Natalyn Hawk, Sungjin Kim, Zhengjia Chen, David A. Kooby, Shishir K. Maithel, Jerome C. Landry, Bassel F. El-Rayes> ;Pancreas. 2013 Nov 1
- 7 citationsExpression of a truncated first exon BCR sequence in chronic myelogenous leukemia cells blocks cell growth and induces cell death.Yan Wang, Jiaxin Liu, Yun Wu, Weiping Luo, Sue-Hwa Lin, Hui Lin, Natalyn Hawk, Tong Sun, J. Q. Guo, Zeev Estrov, Moshe Talpaz, Richard E. Champlin, Ralph B. Arlinghaus> ;Cancer Research. 2001 Jan 1
- Join now to see all
Professional Memberships
- Member
- European Society of Medical OncologyMember
- Member
Industry Relationships
- Associate Director of Clinical Research, Eisai IncEmployee2019 - Present
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: